MWNA
VERV

Marshall Wace North America’s Verve Therapeutics VERV Stock Holding History

Marshall Wace North America’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,451
Closed -$1.11M – 1739
2021
Q2 		$1.11M Buy
+18,451
New +$766K ﹤0.01% 983

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Marshall Wace North America's VERV Position: Q3 2021 in Review

Marshall Wace North America sold out of Verve Therapeutics (VERV) in Q3 2021, closing a stake of 18,451 shares — an estimated $1.11M sold.

Marshall Wace North America first reported a position in VERV in Q2 2021 and held it in 1 quarter. The position peaked at $1.11M in Q2 2021. 73 funds tracked by Wall St. Rank hold VERV as of Q3 2021.

  • Marshall Wace North America reported no remaining Verve Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 18,451 Verve Therapeutics shares in Q3 2021, an estimated $1.11M.
  • Marshall Wace North America first reported a position in Verve Therapeutics in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Verve Therapeutics position peaked at $1.11M in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.